For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Mazdutide
Illustration for Mazdutide

THE PEPSRADAR ENCYCLOPEDIA

Mazdutide

Weight-management research

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Mazdutide · KEY FACTS

Content updated · how dates work

Saved peptides

What is Mazdutide?

Mazdutide is a weekly injected peptide that activates both GLP-1 and glucagon receptors. Eli Lilly discovered it and Innovent develops it in China, where it was approved in 2025 for weight management and for type 2 diabetes, the first drug of its kind approved anywhere. It is not approved in the US or Europe.

Video overview · 3:01

Mazdutide: The First Approved GLP-1 + Glucagon Drug. What the Trials Show

How mazdutide works, the GLORY weight-loss trials, the DREAMS diabetes trials (including the semaglutide head-to-head), side effects, and why it is approved in China but not the US.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

Mazdutide is the first drug that hits both GLP-1 and glucagon to be approved anywhere. China approved it in 2025 for weight loss and type 2 diabetes. It was discovered by Eli Lilly. Here's what the trials show, and what they don't.

Mazdutide is a weekly injection that activates two hormone receptors: GLP-1, which lowers appetite, and glucagon, which is thought to raise energy use and reduce liver fat. Lilly discovered it, and Innovent develops it in China, where it's sold as Xinermei.

Here's the idea. The GLP-1 side lowers appetite. The glucagon side is proposed to burn more energy and clear liver fat. Together they lowered weight and blood sugar in large trials. Whether that beats tirzepatide hasn't been tested.

In GLORY-1, 610 Chinese adults lost about eleven to fourteen percent of their weight over 48 weeks, versus no loss on placebo. In GLORY-2, at a higher dose, people lost about seventeen percent over 60 weeks, versus one and a half. The 'up to twenty percent' you see online comes from the company's own analysis of a subgroup.

In type 2 diabetes, it lowered A1C by about one and a half to two points, and beat dulaglutide on both blood sugar and weight. Against semaglutide, in DREAMS-3, more people reached both their blood-sugar and weight goals: 48 versus 21 percent. But that trial was open-label, used semaglutide's diabetes dose, and so far is only a company press release.

Side effects are mostly stomach and gut. In GLORY-2, about half of people had vomiting or nausea, versus very few on placebo, though only about three percent stopped because of side effects. Heart rate also rose a few beats per minute. And nearly all of the big trials were in Chinese adults.

Mazdutide is approved in China for weight management and type 2 diabetes. It isn't approved in the US or Europe, and Lilly hasn't announced a phase 3 trial or a filing there. No heart-outcomes trial has reported. And the FDA has sent warning letters to sellers of research-labeled mazdutide.

Does it beat Ozempic? Limited: one open-label diabetes trial, reported by the company. Does it beat Zepbound? Unproven: there's no head-to-head. Does it treat fatty liver? Unproven: liver fat fell on scans, but there are no biopsy results yet. And is it legal to buy in the US? No: it isn't FDA-approved.

The bottom line: mazdutide lowered weight and blood sugar in large trials in China, where it's approved. Whether it beats tirzepatide, or protects the heart or liver, is still unknown. For every study and source, see the mazdutide profile on PepsRadar dot com, and subscribe for the next trial breakdown.

Biological role or research focus

Weight-management research.

The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.

Role reference: Phase 2 mazdutide trial in Chinese adults · Nat Commun 2023 ↗

Names you may encounter

IBI362 · LY3305677

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Dual GLP-1 / glucagon receptor agonist
Research focus
Weight-management research
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗

Quick answers

Is Mazdutide FDA approved?
No. No FDA-approved drug contains Mazdutide. Source ↗
Is Mazdutide safe?
Investigational GLP-1/glucagon drug, not FDA-approved. Trials report frequent nausea, vomiting and diarrhea; rare, long-term and heart-related risks are not yet known. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Mazdutide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
Has the FDA taken action over Mazdutide?
Yes. Our records list 3 FDA actions naming it, most recently on October 1, 2026: FDA states it has warned companies illegally selling unapproved drugs containing mazdutide (and other GLP-1 agents) falsely labeled "for research purposes." Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

5 Human research
StudyTypePopulation / model
GLORY-1 (2025)Human randomized trial610 Chinese adults aged 18–75 with obesity, or overweight and an associated condition.
Phase 2 · Chinese adults with overweight or obesity (2023)Human randomized trial248 Chinese adults with overweight or obesity.
Phase 2 · US adults with obesity or overweight (2026)Human randomized trial179 US adults with obesity or overweight and without diabetes.
DREAMS-1 · type 2 diabetes vs placebo (2026)Human randomized trial320 Chinese adults with type 2 diabetes not taking other diabetes medicines.
DREAMS-2 · type 2 diabetes vs dulaglutide (2026)Human randomized trial731 Chinese adults with type 2 diabetes.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2025

GLORY-1

How did weight change versus placebo in GLORY-1?

Population / model
610 Chinese adults aged 18–75 with obesity, or overweight and an associated condition.
Study design
Randomized placebo-controlled phase 3 study with two mazdutide groups; 48-week follow-up.
Main finding
At week 32, mean weight change was −10.09% and −12.55% in the mazdutide groups versus +0.45% with placebo. At week 48, the corresponding changes were −11.00%, −14.01%, and +0.30%.
Limits & context
The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.

Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗

Human randomized trial · 2023

Phase 2 · Chinese adults with overweight or obesity

How much weight did people lose over 24 weeks?

Population / model
248 Chinese adults with overweight or obesity.
Study design
Randomized, double-blind, placebo-controlled; three dose arms, 24 weeks.
Main finding
Average weight change ranged from −6.7% to −11.3% on mazdutide versus +1.0% on placebo. Heart rate rose modestly and returned to baseline after treatment stopped.
Limits & context
Short and limited to Chinese adults; sponsored by the developer.

Source: A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity ↗

Human randomized trial · 2026

Phase 2 · US adults with obesity or overweight

Did the results carry over to a US population?

Population / model
179 US adults with obesity or overweight and without diabetes.
Study design
Randomized, placebo-controlled, multicenter; 48 weeks, with the main comparison at week 32.
Main finding
At week 32, weight fell 7.3% to 18.1% across dose arms versus 0.9% on placebo. Stopping because of side effects, mostly gastrointestinal, was most common in the highest-dose arm.
Limits & context
A phase 2 trial; a US phase 3 program had not been announced when this was checked.

Source: Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial ↗

Human randomized trial · 2026

DREAMS-1 · type 2 diabetes vs placebo

Did mazdutide lower blood sugar in type 2 diabetes?

Population / model
320 Chinese adults with type 2 diabetes not taking other diabetes medicines.
Study design
Randomized, double-blind, placebo-controlled phase 3; 24 weeks.
Main finding
HbA1c fell 1.57 and 2.15 points versus 0.14 on placebo, and weight fell 5.6% and 7.8% versus 1.3%.
Limits & context
Short, in Chinese adults only, and sponsored by the developer.

Source: Mazdutide versus placebo in Chinese adults with type 2 diabetes ↗

Human randomized trial · 2026

DREAMS-2 · type 2 diabetes vs dulaglutide

How did mazdutide compare with an established GLP-1 drug?

Population / model
731 Chinese adults with type 2 diabetes.
Study design
Randomized phase 3 comparison with dulaglutide; 28 weeks.
Main finding
Mazdutide lowered HbA1c by an extra 0.24 to 0.30 points and weight by an extra 3.8% to 5.8% compared with dulaglutide.
Limits & context
Compared with dulaglutide, not with semaglutide or tirzepatide. A separate head-to-head with semaglutide (DREAMS-3) has so far been reported only in a company press release.

Source: Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

46 registered studies name Mazdutide as an intervention; 14 are recruiting or under way, 12 have not started recruiting yet, 19 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042 · Shanghai Zhongshan Hospital
RecruitingNot applicable2026-06-10420
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
NCT07775846 · Huijie Zhang
RecruitingPhase 42026-11-03820
Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes
NCT07924553 · Peking University People's Hospital
Not yet recruitingNot applicable2027-01-01182
Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
NCT07897305 · Beijing Anzhen Hospital
Not yet recruitingNot applicable2026-10-25700
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT06937749 · Innovent Biologics (Suzhou) Co. Ltd.
Active, not recruitingPhase 22025-06-20181
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
NCT07657676 · China National Center for Cardiovascular Diseases
RecruitingPhase 42026-09-14116
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956 · Eli Lilly and Company
RecruitingPhase 22023-11-171481
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
NCT07843862 · Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruitingPhase 22026-10240

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 46 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Emerging pharmacotherapies for obesity: A systematic review. ↗
Pharmacological reviews · 2025 Jan · Journal Article, Systematic Review

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. ↗
Metabolism: clinical and experimental · 2024 Dec · Journal Article, Systematic Review, Network Meta-Analysis, Research Support, Non-U.S. Gov't

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. ↗
BMJ (Clinical research ed.) · 2026 Jul 8 · Systematic Review, Network Meta-Analysis, Journal Article, Comparative Study

Mazdutide: First Approval. ↗
Drugs · 2025 Dec · Journal Article, Review

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Investigational GLP-1/glucagon drug, not FDA-approved. Trials report frequent nausea, vomiting and diarrhea; rare, long-term and heart-related risks are not yet known.

Human safety data: Trials only

Phase 2 and 3 trials, mostly in Chinese adults and up to about a year long, found mainly mild to moderate digestive side effects. China approved it in 2025, but the FDA has not. Long-term, rare and cardiovascular risks are not established.

Warnings for approved drugs in the same class (semaglutide, tirzepatide, liraglutide, dulaglutide), which may apply here too: Diabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problemsBlood thinners or bleeding problemsHeart or blood pressure problems

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Interactions

  • Anesthesia or sedation: GLP-1-based medicines slow stomach emptying, and reviews flag retained stomach contents as a class concern

Serious risks

  • Side effects led more people to stop treatment than placebo in the GLORY-2 trial (2.9% vs 0%)
  • Pancreas and gallbladder problems are discussed as safety concerns for GLP-1-based medicines as a class
  • FDA warns that mazdutide sold 'for research purposes' is unapproved and of unknown quality

Side effects reported in studies

  • nausea
  • vomiting
  • diarrhea
  • decreased appetite

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: GLORY-1 phase 3 trial (N Engl J Med, 2025) ↗ · GLORY-2 randomized trial (JAMA, 2026) ↗ · Mazdutide: First Approval (Drugs, 2025) ↗ · Efficacy and safety of GLP-1 medicines (review) ↗ · FDA: Concerns with unapproved GLP-1 drugs ↗

What the featured evidence can tell us

Gastrointestinal adverse events were mostly mild or moderate in this study. Discontinuation due to adverse events occurred in 1.5%, 0.5%, and 1.0% of the respective groups. These figures do not resolve rare or long-term harms.

Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗

Identity, route, and evidence limits

The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.

Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗

Side effects in the trials

Side effects were mostly gastrointestinal (nausea, vomiting, diarrhea) and usually mild to moderate. Few people stopped because of them in the Chinese phase 3 trials, but up to one in five did in the highest-dose arm of the US phase 2 trial. Heart rate rose by a few beats per minute.

Source: Phase 2 mazdutide trial in US adults · Lancet Diabetes Endocrinol 2026 ↗

Research-labeled mazdutide

FDA has sent warning letters to companies selling "research use only" mazdutide, treating it as an unapproved new drug. Such products are not the trial drug, and their contents and purity are not covered by any of the trials on this page.

Source: FDA warning letter naming research-use mazdutide · Xcel Research 2024 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. Innovent announced China NMPA approval for chronic weight management in June 2025 (company announcement; NMPA record not fetched). If that approval stands, S0 would not apply. source

FDA actions

  • FDA states it has warned companies illegally selling unapproved drugs containing mazdutide (and other GLP-1 agents) falsely labeled "for research purposes." (2026-10-01) source
  • FDA warning letter to a "research peptide" seller (NuScience Peptides) naming "Mazdutide", "Survodutide", retatrutide and other peptides as unapproved new drugs. (2026-08-24) source
  • FDA warning letter to a "research peptide" seller (Prime Sciences) naming mazdutide, cagrilintide and GLP-1 products as unapproved new drugs. (2026-03-31) source

Other notes

  • Innovent announced approval of mazdutide (Xinermei) by China's NMPA for chronic weight management (company press release, June 2025). source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

China's regulator approved mazdutide in June 2025 for chronic weight management and in September 2025 for type 2 diabetes. Nearly all of its phase 3 trials enrolled Chinese adults. Lilly has run phase 2 trials in the US, including one in alcohol use disorder, but had not announced a US phase 3 program or filing when this was checked. No cardiovascular outcomes trial has reported.

Source: China approval for weight management · Innovent 2025 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).

Mechanism & research rationale

Mazdutide is modeled on oxyntomodulin, a gut hormone that acts on two receptors. Its GLP-1 activity lowers appetite and blood sugar, as semaglutide does. Its glucagon activity is proposed to raise energy expenditure and reduce liver fat; glucagon activity is also expected to raise heart rate, which rose by a few beats per minute in trials.

Whether adding glucagon gives more benefit than GLP-1 alone, or than tirzepatide, has not been tested in a head-to-head trial.

Source: Phase 2 mazdutide trial in Chinese adults · Nat Commun 2023 ↗

Molecular structure

Mazdutide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 167312357 ↗

Questions worth asking

  • Can these results rank all weight-management peptides?
  • What population, comparator, and route were actually studied?
  • The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Can these results rank all weight-management peptides?

No. Comparisons across separate trials can differ because of population, duration, comparator, and analysis. A direct comparative trial answers a different question.

Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗

Is mazdutide approved in the US?

No. It is approved only in China. FDA has warned sellers of research-labeled mazdutide that it is an unapproved drug.

Source: FDA warning letter naming mazdutide · NuScience Peptides 2026 ↗

Does mazdutide work better than tirzepatide (Zepbound)?

Unknown. No trial has compared them directly, and comparisons across separate trials cannot settle it.

Source: Mazdutide: first approval · Drugs 2025 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Mazdutide

Download illustration ↓Source record ↗
Mazdutide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.